DURHAM, N.C., March 31, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company has been added to the Russell 2000® Index and the Russell 3000® Index. The addition is effective as of March 31, 2014.
Help employers find you! Check out all the jobs and post your resume.
